Eggermont E, Vanderschueren-Lodeweyckx M, De Nayer P, Smeets E, Vanacker G, Cornette C, Jaeken J, Devlieger H, Eeckels R, Beckers C
Helv Paediatr Acta. 1984 Aug;39(3):209-22.
A prospective study was conducted in order to evaluate thyroid function in 20 healthy and 18 sick preterm infants with postmenstrual ages of 31 weeks or less. The clinical condition of both groups was compared using a "Neonatal Special Care Evolution Score". The effect of thyroid hormone treatment, given from D10 on to the sick infants, was also studied. TSH, thyroid hormone levels (TG, T4, T3, rT3, FT4 and FT3) and TBG were measured by radioimmunoassays at D0, D10, D20, D30 and D40. Healthy preterm infants on D0 have a median TSH level of 22 microU/ml and a high TG level of 200 ng/ml; thereafter, median serum levels decrease to 6 microU/ml and 35 ng/ml respectively. During the same period, median serum T4 is maintained at a low level of about 6-8 micrograms/dl, median serum T3 gradually increases from 80 ng/dl on D0 to 150 ng/dl on D40, and median serum rT3 decreases beyond D10 from a plateau of 200 ng/dl to about 100 ng/dl. In the sick preterm infants before treatment, serum TSH is as in the control group but serum T4, T3 and rT3 on D10 are well below the control values (P = 0.005). In all conditions, there is a significant correlation between serum T4 and FT4, and between serum T3 and FT3. Thyroxine, given to the sick preterm infants from D10 on, brings median serum T4 values closely to the ones of the control group whereas serum levels of TSH and TG are unaffected and similar to those of the healthy preterm infants. Furthermore, thyroxine brings serum rT3 within the range of the control group but leaves median serum T3 at a low level of about 50 ng/dl. On T3 treatment, serum T3 normalizes but rT3 and particularly T4 tend to decline further. In the conditions of this study a significant difference in TBG level is not proven. Although an untreated sick group was not enrolled in the study, thyroid hormone treatment brought the "Neonatal Special Care Evolution Score" of the treated sick infants closer to that of the healthy preterm infants. In the sick preterm infant with failure to thrive on D10, there is an impaired thyroid discharge of T4 in spite of serum TSH values not different from those of the control group.(ABSTRACT TRUNCATED AT 400 WORDS)
为评估20名健康和18名患病的孕龄31周及以下的早产儿的甲状腺功能,进行了一项前瞻性研究。使用“新生儿特殊护理进展评分”对两组的临床状况进行比较。还研究了从出生后第10天开始给予患病婴儿甲状腺激素治疗的效果。在出生后第0天、第10天、第20天、第30天和第40天,通过放射免疫测定法测量促甲状腺激素(TSH)、甲状腺激素水平(甲状腺球蛋白(TG)、甲状腺素(T4)、三碘甲状腺原氨酸(T3)、反三碘甲状腺原氨酸(rT3)、游离甲状腺素(FT4)和游离三碘甲状腺原氨酸(FT3))以及甲状腺素结合球蛋白(TBG)。健康早产儿在出生后第0天的TSH水平中位数为22微单位/毫升,TG水平较高,为200纳克/毫升;此后,血清水平中位数分别降至6微单位/毫升和35纳克/毫升。在同一时期,血清T4中位数维持在约6 - 8微克/分升的低水平,血清T3中位数从出生后第0天的80纳克/分升逐渐增加到出生后第40天的150纳克/分升,血清rT3在出生后第10天之后从200纳克/分升的平台期降至约100纳克/分升。在患病早产儿治疗前,血清TSH与对照组相同,但出生后第10天的血清T4、T3和rT3远低于对照值(P = 0.005)。在所有情况下,血清T4与FT4之间以及血清T3与FT3之间均存在显著相关性。从出生后第10天开始给予患病早产儿甲状腺素,使血清T4中位数水平接近对照组,但TSH和TG的血清水平未受影响,与健康早产儿相似。此外,甲状腺素使血清rT3处于对照组范围内,但血清T3中位数维持在约50纳克/分升的低水平。在T3治疗时,血清T3恢复正常,但rT3尤其是T4往往会进一步下降。在本研究条件下,未证实TBG水平存在显著差异。尽管未将未治疗的患病组纳入研究,但甲状腺激素治疗使治疗的患病婴儿的“新生儿特殊护理进展评分”更接近健康早产儿。在出生后第10天生长发育不良的患病早产儿中,尽管血清TSH值与对照组无异,但甲状腺T4的释放受损。(摘要截短至400字)